PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaStephen M. Ansell, Philippe Armand|New England Journal of Medicine|2014Cited by 3.5k
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S. Davids, Robert J. Soiffer, Haesook T. Kim et al.|New England Journal of Medicine|2016Cited by 595
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Jillian L. Scavone, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A. Thompson, Anita M. Engh, Yinghong Wang et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 484
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaChristopher J. Gibson, Benjamin L. Ebert, R. Coleman Lindsley et al.|Journal of Clinical Oncology|2017Cited by 468